Pacer Advisors Inc. Acquires 75,759 Shares of ANI Pharmaceuticals, Inc. $ANIP

Pacer Advisors Inc. grew its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 1,821.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 79,919 shares of the specialty pharmaceutical company’s stock after acquiring an additional 75,759 shares during the period. Pacer Advisors Inc. owned 0.36% of ANI Pharmaceuticals worth $6,309,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Advisors Asset Management Inc. bought a new stake in ANI Pharmaceuticals in the first quarter worth $28,000. Hantz Financial Services Inc. boosted its stake in shares of ANI Pharmaceuticals by 70.3% during the 4th quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock worth $48,000 after acquiring an additional 249 shares in the last quarter. Kemnay Advisory Services Inc. acquired a new position in shares of ANI Pharmaceuticals during the 4th quarter valued at about $48,000. State of Wyoming acquired a new position in shares of ANI Pharmaceuticals during the 2nd quarter valued at about $50,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of ANI Pharmaceuticals by 30.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,091 shares of the specialty pharmaceutical company’s stock valued at $86,000 after acquiring an additional 253 shares in the last quarter. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Performance

Shares of ANIP opened at $79.49 on Monday. The stock’s 50-day moving average price is $80.13 and its 200 day moving average price is $79.30. The company has a quick ratio of 2.52, a current ratio of 3.12 and a debt-to-equity ratio of 1.06. The firm has a market capitalization of $1.81 billion, a price-to-earnings ratio of 20.12 and a beta of 0.44. ANI Pharmaceuticals, Inc. has a 12-month low of $62.60 and a 12-month high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, topping analysts’ consensus estimates of $1.28 by $0.77. The company had revenue of $237.46 million during the quarter, compared to the consensus estimate of $207.63 million. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The company’s quarterly revenue was up 20.5% on a year-over-year basis. During the same quarter last year, the company earned $1.70 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, research analysts predict that ANI Pharmaceuticals, Inc. will post 8.07 earnings per share for the current year.

Insider Buying and Selling

In other ANI Pharmaceuticals news, CEO Nikhil Lalwani sold 55,000 shares of the firm’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $77.57, for a total transaction of $4,266,350.00. Following the completion of the transaction, the chief executive officer owned 349,889 shares in the company, valued at $27,140,889.73. This trade represents a 13.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Ori Gutwerg sold 2,772 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $79.50, for a total value of $220,374.00. Following the completion of the sale, the senior vice president owned 78,696 shares in the company, valued at approximately $6,256,332. This represents a 3.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 79,016 shares of company stock worth $6,195,991. Insiders own 8.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on ANIP shares. Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ANI Pharmaceuticals in a report on Monday, June 1st. Five equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $107.33.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.